Emerging Technologies for Assessing HER2 Amplification
Identifieur interne : 008358 ( Main/Exploration ); précédent : 008357; suivant : 008359Emerging Technologies for Assessing HER2 Amplification
Auteurs : Fridirique Penault-Llorca [France] ; Michael Bilous [Australie] ; Mitch Dowsett [Royaume-Uni] ; Wedad Hanna [Canada] ; Robert Yoshiyuki Osamura [Japon] ; Josef Rüschoff [Allemagne] ; Marc Van De Vijver [Pays-Bas]Source :
- American journal of clinical pathology [ 0002-9173 ] ; 2009.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Argent.
English descriptors
- KwdEn :
Abstract
Patients with human epidermal growth, factor receptor-2 (HER2)+ breast cancer are eligible for trastuzumab treatment; therefore, accurate assessment of HER2 status is essential. Until recently, only 2 methods were validated for determining the HER2 status of breast tumors in the routine diagnostic setting: immunohistochemical analysis and fluorescence in situ hybridization (FISH). Recently, bright-field in situ hybridization techniques such as chromogenic in situ hybridization (CISH) and silver-enhanced in situ hybridization (SISH), which combine features of immunohistochemical analysis and FISH, have been introduced for the determination ofHER2 status. These new techniques use a peroxidase enzyme-labeled probe with chromogenic detection, instead of a fluorescent- labeled probe, allowing results to be visualized by standard bright-field microscopy. Thus, the histologic features and HER2 status of a specimen can be evaluated in parallel. Moreover, signals do not decay over time. This review discusses recent publications regarding CISH and SISH testing, including results scoring and concordance between FISH and immunohistochemical analysis.
Affiliations:
- Allemagne, Australie, Canada, France, Japon, Pays-Bas, Royaume-Uni
- Angleterre, Auvergne (région administrative), Auvergne-Rhône-Alpes, District de Kassel, Grand Londres, Hesse (Land), Hollande-Septentrionale
- Amsterdam, Cassel (Hesse), Clermont-Ferrand, Londres
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 002B43
- to stream PascalFrancis, to step Curation: 003481
- to stream PascalFrancis, to step Checkpoint: 002B59
- to stream Main, to step Merge: 008B28
- to stream Main, to step Curation: 008358
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Emerging Technologies for Assessing HER2 Amplification</title><author><name sortKey="Penault Llorca, Fridirique" sort="Penault Llorca, Fridirique" uniqKey="Penault Llorca F" first="Fridirique" last="Penault-Llorca">Fridirique Penault-Llorca</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Pathology, Centre Jean Perrin and EA 4233, University of Auvergne</s1><s2>Clermont-Ferrand</s2><s3>FRA</s3><sZ>1 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Auvergne (région administrative)</region><settlement type="city">Clermont-Ferrand</settlement></placeName></affiliation></author><author><name sortKey="Bilous, Michael" sort="Bilous, Michael" uniqKey="Bilous M" first="Michael" last="Bilous">Michael Bilous</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute of Clinical Pathology and Medical Research, Westmead Hospital</s1><s2>Westmead</s2><s3>AUS</s3><sZ>2 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Westmead</wicri:noRegion></affiliation></author><author><name sortKey="Dowsett, Mitch" sort="Dowsett, Mitch" uniqKey="Dowsett M" first="Mitch" last="Dowsett">Mitch Dowsett</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Department of Biochemistry, the Royal Marsden Hospital</s1><s2>London</s2><s3>GBR</s3><sZ>3 aut.</sZ></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Hanna, Wedad" sort="Hanna, Wedad" uniqKey="Hanna W" first="Wedad" last="Hanna">Wedad Hanna</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Sunnybrook and Women's College Health Science Centre</s1><s2>Toronto</s2><s3>CAN</s3><sZ>4 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Sunnybrook and Women's College Health Science Centre</wicri:noRegion></affiliation></author><author><name sortKey="Yoshiyuki Osamura, Robert" sort="Yoshiyuki Osamura, Robert" uniqKey="Yoshiyuki Osamura R" first="Robert" last="Yoshiyuki Osamura">Robert Yoshiyuki Osamura</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Pathology, Tokai University School of Medicine</s1><s2>Kanagawa</s2><s3>JPN</s3><sZ>5 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Kanagawa</wicri:noRegion></affiliation></author><author><name sortKey="Ruschoff, Josef" sort="Ruschoff, Josef" uniqKey="Ruschoff J" first="Josef" last="Rüschoff">Josef Rüschoff</name><affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Institute of Pathology, Klinikum Kassel</s1><s2>Kassel</s2><s3>DEU</s3><sZ>6 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Kassel</region><settlement type="city">Cassel (Hesse)</settlement></placeName></affiliation></author><author><name sortKey="Van De Vijver, Marc" sort="Van De Vijver, Marc" uniqKey="Van De Vijver M" first="Marc" last="Van De Vijver">Marc Van De Vijver</name><affiliation wicri:level="3"><inist:fA14 i1="07"><s1>Department of Pathology, the Netherlands Cancer Institute</s1><s2>Amsterdam</s2><s3>NLD</s3><sZ>7 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">09-0413033</idno><date when="2009">2009</date><idno type="stanalyst">PASCAL 09-0413033 INIST</idno><idno type="RBID">Pascal:09-0413033</idno><idno type="wicri:Area/PascalFrancis/Corpus">002B43</idno><idno type="wicri:Area/PascalFrancis/Curation">003481</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">002B59</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">002B59</idno><idno type="wicri:doubleKey">0002-9173:2009:Penault Llorca F:emerging:technologies:for</idno><idno type="wicri:Area/Main/Merge">008B28</idno><idno type="wicri:Area/Main/Curation">008358</idno><idno type="wicri:Area/Main/Exploration">008358</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Emerging Technologies for Assessing HER2 Amplification</title><author><name sortKey="Penault Llorca, Fridirique" sort="Penault Llorca, Fridirique" uniqKey="Penault Llorca F" first="Fridirique" last="Penault-Llorca">Fridirique Penault-Llorca</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Pathology, Centre Jean Perrin and EA 4233, University of Auvergne</s1><s2>Clermont-Ferrand</s2><s3>FRA</s3><sZ>1 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Auvergne (région administrative)</region><settlement type="city">Clermont-Ferrand</settlement></placeName></affiliation></author><author><name sortKey="Bilous, Michael" sort="Bilous, Michael" uniqKey="Bilous M" first="Michael" last="Bilous">Michael Bilous</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute of Clinical Pathology and Medical Research, Westmead Hospital</s1><s2>Westmead</s2><s3>AUS</s3><sZ>2 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Westmead</wicri:noRegion></affiliation></author><author><name sortKey="Dowsett, Mitch" sort="Dowsett, Mitch" uniqKey="Dowsett M" first="Mitch" last="Dowsett">Mitch Dowsett</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Department of Biochemistry, the Royal Marsden Hospital</s1><s2>London</s2><s3>GBR</s3><sZ>3 aut.</sZ></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Hanna, Wedad" sort="Hanna, Wedad" uniqKey="Hanna W" first="Wedad" last="Hanna">Wedad Hanna</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Sunnybrook and Women's College Health Science Centre</s1><s2>Toronto</s2><s3>CAN</s3><sZ>4 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Sunnybrook and Women's College Health Science Centre</wicri:noRegion></affiliation></author><author><name sortKey="Yoshiyuki Osamura, Robert" sort="Yoshiyuki Osamura, Robert" uniqKey="Yoshiyuki Osamura R" first="Robert" last="Yoshiyuki Osamura">Robert Yoshiyuki Osamura</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Pathology, Tokai University School of Medicine</s1><s2>Kanagawa</s2><s3>JPN</s3><sZ>5 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Kanagawa</wicri:noRegion></affiliation></author><author><name sortKey="Ruschoff, Josef" sort="Ruschoff, Josef" uniqKey="Ruschoff J" first="Josef" last="Rüschoff">Josef Rüschoff</name><affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Institute of Pathology, Klinikum Kassel</s1><s2>Kassel</s2><s3>DEU</s3><sZ>6 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Kassel</region><settlement type="city">Cassel (Hesse)</settlement></placeName></affiliation></author><author><name sortKey="Van De Vijver, Marc" sort="Van De Vijver, Marc" uniqKey="Van De Vijver M" first="Marc" last="Van De Vijver">Marc Van De Vijver</name><affiliation wicri:level="3"><inist:fA14 i1="07"><s1>Department of Pathology, the Netherlands Cancer Institute</s1><s2>Amsterdam</s2><s3>NLD</s3><sZ>7 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author></analytic><series><title level="j" type="main">American journal of clinical pathology</title><title level="j" type="abbreviated">Am. j. clin. pathol.</title><idno type="ISSN">0002-9173</idno><imprint><date when="2009">2009</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">American journal of clinical pathology</title><title level="j" type="abbreviated">Am. j. clin. pathol.</title><idno type="ISSN">0002-9173</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anatomic pathology</term><term>Breast cancer</term><term>C-Onc gene</term><term>Chromogenic In Situ Hybridization</term><term>Diagnosis</term><term>Fluorescence in situ hybridization</term><term>Gene amplification</term><term>Human Epidermal growth factor Receptor 2</term><term>Immunohistochemistry</term><term>In situ hybridization</term><term>Protooncogene</term><term>Review</term><term>Silver</term><term>erbB2 Gene</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Cancer du sein</term><term>Argent</term><term>Gène onc cellulaire</term><term>Immunohistochimie</term><term>Protooncogène</term><term>Gène erbB2</term><term>Hybridation in situ fluorescence</term><term>Amplification génique</term><term>Anatomopathologie</term><term>Article synthèse</term><term>Diagnostic</term><term>Récepteur HER2</term><term>Technique CISH</term><term>Hybridation in situ</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Argent</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Patients with human epidermal growth, factor receptor-2 (HER2)+ breast cancer are eligible for trastuzumab treatment; therefore, accurate assessment of HER2 status is essential. Until recently, only 2 methods were validated for determining the HER2 status of breast tumors in the routine diagnostic setting: immunohistochemical analysis and fluorescence in situ hybridization (FISH). Recently, bright-field in situ hybridization techniques such as chromogenic in situ hybridization (CISH) and silver-enhanced in situ hybridization (SISH), which combine features of immunohistochemical analysis and FISH, have been introduced for the determination ofHER2 status. These new techniques use a peroxidase enzyme-labeled probe with chromogenic detection, instead of a fluorescent- labeled probe, allowing results to be visualized by standard bright-field microscopy. Thus, the histologic features and HER2 status of a specimen can be evaluated in parallel. Moreover, signals do not decay over time. This review discusses recent publications regarding CISH and SISH testing, including results scoring and concordance between FISH and immunohistochemical analysis.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Canada</li><li>France</li><li>Japon</li><li>Pays-Bas</li><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Auvergne (région administrative)</li><li>Auvergne-Rhône-Alpes</li><li>District de Kassel</li><li>Grand Londres</li><li>Hesse (Land)</li><li>Hollande-Septentrionale</li></region><settlement><li>Amsterdam</li><li>Cassel (Hesse)</li><li>Clermont-Ferrand</li><li>Londres</li></settlement></list><tree><country name="France"><region name="Auvergne-Rhône-Alpes"><name sortKey="Penault Llorca, Fridirique" sort="Penault Llorca, Fridirique" uniqKey="Penault Llorca F" first="Fridirique" last="Penault-Llorca">Fridirique Penault-Llorca</name></region></country><country name="Australie"><noRegion><name sortKey="Bilous, Michael" sort="Bilous, Michael" uniqKey="Bilous M" first="Michael" last="Bilous">Michael Bilous</name></noRegion></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Dowsett, Mitch" sort="Dowsett, Mitch" uniqKey="Dowsett M" first="Mitch" last="Dowsett">Mitch Dowsett</name></region></country><country name="Canada"><noRegion><name sortKey="Hanna, Wedad" sort="Hanna, Wedad" uniqKey="Hanna W" first="Wedad" last="Hanna">Wedad Hanna</name></noRegion></country><country name="Japon"><noRegion><name sortKey="Yoshiyuki Osamura, Robert" sort="Yoshiyuki Osamura, Robert" uniqKey="Yoshiyuki Osamura R" first="Robert" last="Yoshiyuki Osamura">Robert Yoshiyuki Osamura</name></noRegion></country><country name="Allemagne"><region name="Hesse (Land)"><name sortKey="Ruschoff, Josef" sort="Ruschoff, Josef" uniqKey="Ruschoff J" first="Josef" last="Rüschoff">Josef Rüschoff</name></region></country><country name="Pays-Bas"><region name="Hollande-Septentrionale"><name sortKey="Van De Vijver, Marc" sort="Van De Vijver, Marc" uniqKey="Van De Vijver M" first="Marc" last="Van De Vijver">Marc Van De Vijver</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 008358 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 008358 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:09-0413033
|texte= Emerging Technologies for Assessing HER2 Amplification
}}
| This area was generated with Dilib version V0.6.33. |  |